Drug Profile
Hib-hepatitis B vaccine - Merck & Co
Alternative Names: ComvaxLatest Information Update: 30 Oct 2000
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer CSL; Merck & Co
- Class Haemophilus vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Haemophilus infections; Hepatitis B
Most Recent Events
- 30 Oct 2000 CSL has licensed Comvax® in Australia
- 13 Oct 2000 Registered for Haemophilus infections in Australia (IM)
- 13 Oct 2000 Registered for Hepatitis B in Australia (IM)